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Introduction {#jcsm12133-sec-0005}
============

Sarcopenia in the aging population has been associated with frailty, mobility limitation, and increased mortality.[1](#jcsm12133-bib-0001){ref-type="ref"}, [2](#jcsm12133-bib-0002){ref-type="ref"}, [3](#jcsm12133-bib-0003){ref-type="ref"} Sarcopenia occurs almost universally in men receiving androgen deprivation therapy (ADT) for prostate cancer, consequent to profound testosterone deficiency. Developing interventions to minimize long‐term adverse effects of ADT in men with localized prostate cancer is paramount, particularly as 5‐year cancer‐specific survival rates exceed 95%.[4](#jcsm12133-bib-0004){ref-type="ref"}

Muscle mass declines by 2--4% per year with ADT and occurs maximally in the first 6 to 12 months.[5](#jcsm12133-bib-0005){ref-type="ref"}, [6](#jcsm12133-bib-0006){ref-type="ref"}, [7](#jcsm12133-bib-0007){ref-type="ref"} This has been associated with subjective reports of increased fatigue and decreased quality of life.[8](#jcsm12133-bib-0008){ref-type="ref"} However, whether this translates into deficits in muscle strength or function is not known, with inconsistent results demonstrated. This may be because previous tests of muscle function (such as leg‐press or chair‐rise time) are relatively insensitive and may not be assessing functional deficits affected by ADT. It is also unclear whether ADT uniformly decreases muscle mass and function, or if individual muscles differ in testosterone sensitivity as seen in rodents.[9](#jcsm12133-bib-0009){ref-type="ref"}

Video‐based motion capture technology can digitally record human movements in three dimensions with high precision.[10](#jcsm12133-bib-0010){ref-type="ref"}, [11](#jcsm12133-bib-0011){ref-type="ref"}, [12](#jcsm12133-bib-0012){ref-type="ref"} When these data are combined with recordings of ground reaction force and computerized musculoskeletal modelling, it is possible to generate detailed biomechanical analyses of muscle function, including the quantification of individual lower‐limb joint torques as well as estimates of individual muscle forces and their contributions to the functional tasks of support, propulsion, and mediolateral balance during walking.[12](#jcsm12133-bib-0012){ref-type="ref"} Extensively validated and used for over two decades in the biomechanics field, this approach has applications in animation, sports science, and robotics. The combination of computerized musculoskeletal modelling and three‐dimensional gait analysis has not previously been applied to longitudinal studies in humans. We used this methodology in this prospective controlled study to assess skeletal muscle function in men undergoing ADT.

We hypothesized that ADT leads to abnormalities in lower‐limb biomechanical function during gait and has differential effects on individual muscles.

Materials and methods {#jcsm12133-sec-0006}
=====================

Methods {#jcsm12133-sec-1007}
-------

We conducted a prospective 12‐month case--control study of 63 age‐matched and radiotherapy‐matched, ADT‐naïve, ambulatory men with localized non‐metastatic prostate cancer recruited from an outpatient clinic for men with prostate cancer at a tertiary referral hospital (Austin Health, Melbourne, Australia). The study was approved by Human Research Ethics Committees at Austin Health and the University of Melbourne (Victoria, Australia). All participants provided written and informed consent.

Cases were 34 men newly commencing ADT planned for \>12 months. All cases received gonadotropin‐releasing hormone agonists as ADT. Controls were 29 men not receiving ADT over 12 months. Prostate cancer controls were specifically recruited to control for a cancer diagnosis and ascertain the specific effect of testosterone deficiency alone. We did not include a control group of healthy older men, because this study was designed to specifically examine the effects of ADT. Groups were matched for age, body mass index, medical co‐morbidities, radiotherapy treatment, and baseline testosterone level. All men were independently living in the community, ambulant, fully active, unrestricted in their physical activities with normal performance status (Eastern Co‐operative Oncology Group performance status 0), and had no evidence of metastases on staging investigations at entry to the study. Men were excluded if they had evidence of androgen deficiency (baseline total testosterone \<10 nmol/L), neuromuscular disease, limitation in their exercise tolerance, active cardiac, respiratory or joint disease, or if they required a walking aid. Subjects underwent assessments at 0, 6, and 12 months. Twenty‐nine men receiving ADT and 24 controls had complete gait analysis data available at all time points.

Each assessment included biomechanical gait analysis, serum biochemistry, hand‐grip strength (kilogram) (Jamar Hand Dynamometer, S.I. instruments, Adelaide, Australia), and Minnesota Leisure‐time Physical Activity Questionnaire.[13](#jcsm12133-bib-0013){ref-type="ref"} Lean mass was measured by dual‐energy X‐ray absorptiometry (Prodigy version 7.51; GE Lunar, Madison, WI, USA) at 0 and 12 months (coefficient of variation \<2% for repeated scans).[14](#jcsm12133-bib-0014){ref-type="ref"} Dual‐energy X‐ray absorptiometry was not performed at 6 months to minimize radiation exposure. All men received general lifestyle education for prostate cancer and were encouraged to exercise regularly and maintain healthy dietary habits.

Biochemical assays {#jcsm12133-sec-0007}
------------------

Fasting serum total testosterone was determined using an immunometric testosterone assay (Access, Beckman Coulter, Inc.) with a minimum detection limit of 0.4 nmol/L and an inter‐assay variation of 5.7% at 4.7 nmol/L. The reference range was 10.0--27.6 nmol/L, derived from an independent reference panel.[15](#jcsm12133-bib-0015){ref-type="ref"} Prostate‐specific antigen (PSA) was determined using electrochemiluminescent immunoassay (Cobas e602, Roche Diagnostics) with a minimum detection limit of 0.03 µg/L and an inter‐assay variation of 1.83% at 0.63 µg/L.

Biomechanical gait experiments {#jcsm12133-sec-0008}
------------------------------

Participants performed level walking in the Biomotion Laboratory at the University of Melbourne (Australia). Two assessors performed all gait experiments at each visit (A. G. S. and A. S. C.). Experimental data were measured and processed as previously described and accepted in the biomechanics field.[16](#jcsm12133-bib-0016){ref-type="ref"}, [17](#jcsm12133-bib-0017){ref-type="ref"} Briefly, the three‐dimensional positions of 45 reflective markers attached to the bony prominences of each subject were recorded with nine cameras positioned circumferentially around the laboratory using a video motion capture system (VICON, Oxford Metrics Ltd., Oxford) sampling at a rate of 120 Hz (*Figure* [1](#jcsm12133-fig-0001){ref-type="fig"}). Ground reaction forces were measured using three force plates (AMTI, Watertown, MA) embedded in the floor. Each subject performed five walking trials (self‐selected speed), and the mean of two trials where the feet landed within the boundaries of the force plates were analysed. Data were recorded across one full gait cycle (ipsilateral heel‐strike to ipsilateral heel‐strike) and further sub‐divided into stance and swing phases (*Figure* [2](#jcsm12133-fig-0002){ref-type="fig"}). Lower‐limb joint angles represented in the sagittal plane and ground reaction forces are highly reproducible (coefficients of multiple correlations 0.968--0.995 and 0.942--0.997, respectively).[10](#jcsm12133-bib-0010){ref-type="ref"}, [11](#jcsm12133-bib-0011){ref-type="ref"} The coefficient of variation for repeated measurements of step width, stride length, and walking speed is 1.7--6.1%.[11](#jcsm12133-bib-0011){ref-type="ref"}

![Representative participant in the Biomotion Laboratory. Anterior view of subject fitted with 45 reflective markers standing on one of the three ground reaction force plates embedded in the laboratory floor. Nine cameras were positioned circumferentially around the laboratory. Subject photographed has provided full consent for publication of image.](JCSM-8-102-g001){#jcsm12133-fig-0001}

![The gait cycle. Depicted is one gait cycle, with the right leg dominant, beginning at right heel strike and ending at the next right heel strike. HS, heel strike; CTO, contralateral toe off the ground; CHS, contralateral heel strike; TO, toe off. The stance phase is defined as the time the dominant (right) foot is on the ground, which is 62% of one gait cycle. The swing phase is the time the dominant foot is off the ground and comprises 38% of one gait cycle. Muscle activation varies for each individual muscle as a function of time during the gait cycle. The gluteus maximus, gluteus medius, hamstrings, and quadriceps are active during early stance (from right heel strike to just after contralateral toe‐off) to generate support whereas the iliopsoas, gastrocnemius, soleus, and plantarflexor invertors are active during mid‐late stance to accelerate the body forward in preparation for the subsequent swing phase.](JCSM-8-102-g002){#jcsm12133-fig-0002}

### Musculoskeletal model of the body {#jcsm12133-sec-0009}

Biomechanical gait experiments provided precise position, dimensions, ground reaction forces, velocity, and acceleration of each subject and each subject\'s joints and body segments. This raw data then underwent computerized musculoskeletal modelling to determine outcomes of lower‐limb joint torques, individual muscle forces, and individual muscle contributions to acceleration of the body\'s centre of mass.[18](#jcsm12133-bib-0018){ref-type="ref"} Using physics‐based simulation of the human body, computerized musculoskeletal modelling can delineate how individual muscles and joints interact to produce movement. Three‐dimensional, muscle‐actuated simulations can accurately reproduce gait and other movement dynamics of individual patients and can be used to determine maximum isometric force and joint torque that a muscle can develop at any position and analyse how muscles contribute to motions (induced accelerations of the body\'s centre of mass) during walking or running. We used a generic three‐dimensional musculoskeletal model implemented in an open‐source biomechanics simulation software package to calculate net joint torques and lower‐limb muscle forces.[19](#jcsm12133-bib-0019){ref-type="ref"} The model is primarily of the lower extremities with the skeleton modelled as 14 segments with 23 degrees of freedom and 92 muscle‐tendon actuators to represent 76 muscles in the lower limbs and torso (*Figure* [3](#jcsm12133-fig-0003){ref-type="fig"}). Generic models were scaled to individual participant\'s body dimensions to develop subject‐specific models.

![Muscle‐tendon actuators in a musculoskeletal model. Muscle‐tendon actuators shown in red used in the computerized musculoskeletal model representing lower‐limb and torso muscles of a subject during stance phase beginning with right heel strike through to right toe‐off.](JCSM-8-102-g003){#jcsm12133-fig-0003}

### Net joint torques and lower‐limb muscle forces {#jcsm12133-sec-0010}

Net torques measured in Newton‐metre represent the sum of all the forces of the muscles acting to rotate a joint. The net torques developed about the hip, knee, and ankle joints were calculated using a standard inverse dynamics approach in the computerized musculoskeletal model. The joint torques were then decomposed into individual muscle forces (measured in Newtons) using a mathematical theory known as static optimization, which minimized the sum of all muscle activations squared, subject to each muscle\'s force--length--velocity properties.[19](#jcsm12133-bib-0019){ref-type="ref"}

### Individual muscle contributions to centre of mass accelerations {#jcsm12133-sec-0011}

The function of an individual muscle can be described by how it contributes to moving the body during a task (such as walking), that is, by its contribution to acceleration of the body\'s centre of mass. The body accelerates in three directions during walking; vertically (upwards to maintain an erect position), anteroposteriorly (braking followed by propulsion), and mediolaterally (sideways). Using the computerized musculoskeletal model, a 'pseudo‐inverse force decomposition' method was used to compute the contribution of each muscle force to the acceleration of the centre of mass of the body in these three directions.[20](#jcsm12133-bib-0020){ref-type="ref"} All results were time‐normalized to the stance phase and averaged separately across all participants. Muscle forces were normalized to each participant\'s body weight (BW) whereas joint torques were normalized to BW multiplied by height (BW × H).

### Step width, walking speed, and stride length {#jcsm12133-sec-0012}

Step width was calculated based on the mediolateral distance between the right heel marker at right heel strike and the left heel marker at left heel strike. Walking speed was taken as the average speed of the reflective marker attached to the sacrum. Stride length was calculated by dividing the average speed calculated between consecutive heel strikes by time.

Sample size determination {#jcsm12133-sec-0013}
-------------------------

Power calculations were based on walking speed, knee flexion torque, and hand‐grip strength as main outcomes. For 80% power (5% significance) to demonstrate a difference in joint torque of 0.3 N/m^2^ (SD 0.2), walking speed of 0.13 m/s (SD 0.07), and hand grip strength of 4.0 kg (SD 5.0), the sample size required for each cohort was 7, 5, and 25 men, respectively.[21](#jcsm12133-bib-0021){ref-type="ref"}, [22](#jcsm12133-bib-0022){ref-type="ref"}, [23](#jcsm12133-bib-0023){ref-type="ref"} It was estimated that 30 men per cohort would be required to allow for 20% drop‐out.

Statistical analysis {#jcsm12133-sec-0014}
--------------------

Non‐normally distributed clinical variables including testosterone, PSA, and physical activity are presented as median and interquartile range (IQR) (*Tables* [1](#jcsm12133-tbl-0001){ref-type="table-wrap"} and [2](#jcsm12133-tbl-0002){ref-type="table-wrap"}). For these parameters, comparisons between groups at baseline were made using Wilcoxon rank‐sum test for continuous variables or χ^2^ test for frequencies. Gait variables were normally distributed and are presented as mean ± standard deviation (*Tables* [3](#jcsm12133-tbl-0003){ref-type="table-wrap"} and [4](#jcsm12133-tbl-0004){ref-type="table-wrap"}). A linear mixed model was used to measure the difference in the change from baseline to 12 months between the ADT group and the control group. The fixed effects in the model were group, time, and their interaction, and the random effect was subject identity. The model accounts for between‐subject and within‐subject effects, where the between‐subject effect is group, within‐subject effect is time, and the interaction between group and time represents the change across groups over time. As a summary measure, the mean difference (95% confidence interval) which is the difference in the change across groups over time, and the corresponding *P* value are reported. A *P* \< 0.05 was considered significant. Statistical analysis was performed using [spss]{.smallcaps} Statistics software (version 22.0.0.0 for Mac) (IBM Corporation, New York, USA).

###### 

Baseline characteristics of the study participants

  Baseline characteristic             ADT group           Controls            *P* value
  ----------------------------------- ------------------- ------------------- -----------
  Age (years)                         67.6 (64.6, 72.0)   70.6 (65.3, 72.9)   0.48
  Body mass index (kg/m^2^)           27.8 (25.4, 31.5)   27.2 (26.0, 31.8)   0.75
  Prostate cancer Gleason score       9 (8, 9)            7 (7, 7)            \<0.001
  Concurrent radiotherapy treatment   94.1%               89.7%               0.51
  Total testosterone (nmol/L)         14.1 (10.2, 17.6)   15.0 (11.1, 16.9)   0.91
  PSA (µg/L)                          3.62 (0.21, 18.7)   0.05 (0.03, 0.28)   \<0.001
  Haemoglobin (g/L)                   149 (140, 157)      150 (142, 155)      0.66
  Medical co‐morbidities                                                      
  Ischaemic heart disease             17.6%               17.2%               1.00
  Diabetes mellitus                   14.7%               17.2%               1.00
  Liver disease                       0%                  0%                  1.00
  Chronic kidney disease              0%                  0%                  1.00
  Hypertension                        58.8%               58.6%               1.00

ADT, androgen deprivation treatment; PSA, prostate‐specific antigen.

Data presented are median (interquartile range) or proportions (%). *P* \< 0.05 were considered statistically significant between groups (Wilcoxon‐sum rank test or χ^2^ test for frequencies). Prostate cancer Gleason score \<7, low‐moderate risk; 7, intermediate risk; 8--10, high risk prostate cancer.

###### 

Differences in clinical parameters across groups over time

  Clinical values                 ADT group (*n* = 34)                                               Controls (*n* = 29)       Mean difference (95% CI)   *P* value
  ------------------------------- ------------------------------------------------------------------ ------------------------- -------------------------- -----------
  Total testosterone (nmol/L)                                                                                                                             
  0 months                        14.1 (10.2, 17.6)                                                  15.0 (11.1, 16.9)                                    
  6 months                        0.40 (0.30, 0.57)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     14.3 (9.90, 17.2)                                    
  12 months                       0.40 (0.30, 0.50)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     14.8 (11.2, 15.6)         −13.0 (−15.4, −10.7)       \<0.001
  PSA (µg/L)                                                                                                                                              
  0 months                        3.62 (0.21, 18.7)                                                  0.05 (0.03, 0.28)                                    
  6 months                        0.03 (0.03, 0.11)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     0.03 (0.03, 0.21)                                    
  12 months                       0.03 (0.03, 0.04)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     0.03 (0.03, 0.28)         −21.3 (−35.1, −8.2)        0.002
  Handgrip strength (kg)                                                                                                                                  
  0 months                        41.5 (36.0, 44.0)                                                  40.0 (34.0, 45.0)                                    
  6 months                        36.0 (32.0, 42.0)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     41.0 (34.0, 46.0)                                    
  12 months                       38.0 (31.0, 43.0)[\*\*\*](#jcsm12133-note-0008){ref-type="fn"}     43.0 (37.0, 48.0)         −4.66 (−7.09, −2.25)       \<0.001
  Physical activity (kcal/week)                                                                                                                           
  0 months                        1600 (1160, 3305)                                                  1599 (866, 2452)                                     
  6 months                        1668 (688, 3260)                                                   1336 (516, 2449)                                     
  12 months                       1525 (925, 2744)                                                   1195 (780, 1049)          105 (−301, 511)            0.73
  Lean mass (g)                                                                                                                                           
  0 months                        55029 (50 571, 60 589)                                             55 302 (51 380, 60 516)                              
  12 months                       53 187 (49 423, 55 785)[\*](#jcsm12133-note-0006){ref-type="fn"}   54 485 (51 551, 58 669)   −1453 (−190, −2716)        0.03

ADT, androgen deprivation treatment; CI, confidence interval; PSA, prostate‐specific antigen.

Data are presented as median (interquartile range). Mean Difference refers to the between group difference, which is the difference in the change in the mean of the ADT group over change in the mean of the control group over 12 months and is presented with \[95% confidence interval (CI)\] and *P* value (determined from the interaction effect of the mixed model). *P* \< 0.05 were considered statistically significant and refers to overall significance of the change between groups during follow‐up.

*P* \< 0.05.

*P* \< 0.01.

*P* \< 0.001 refers to a significant within group difference in the mean 12 month value and the mean 0 month value within the group (determined from the time effect of the mixed model and paired *t*‐test). Handgrip strength was measured in the dominant hand, best of three attempts. Self‐reported physical activity was measured by the Minnesota Leisure Time Physical Activity Questionnaire.[13](#jcsm12133-bib-0013){ref-type="ref"} Lean mass was only measured at 0 and 12 months.

###### 

Peak joint torques

  Peak torque (N m/kg)                       ADT group (*n* = 29)                                         Controls (*n* = 24)                                          Mean difference (95% CI)   *P* value
  ------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ -------------------------- -----------
  Hip flexion during late stance                                                                                                                                                                  
  0 months                                   0.806 ± 0.124                                                0.801 ± 0.164                                                                           
  6 months                                   0.683 ± 0.152                                                0.691 ± 0.172                                                                           
  12 months                                  0.623 ± 0.140[\*](#jcsm12133-note-0011){ref-type="fn"}       0.728 ± 0.208[\*](#jcsm12133-note-0011){ref-type="fn"}       −0.108 (−0.189, −0.028)    0.009
  Hip extension during early stance                                                                                                                                                               
  0 months                                   0.872 ± 0.247                                                0.931 ± 0.193                                                                           
  6 months                                   0.892 ± 0.185                                                0.997 ± 0.248                                                                           
  12 months                                  0.988 ± 0.169[\*\*\*](#jcsm12133-note-0013){ref-type="fn"}   0.996 ± 0.201[\*\*\*](#jcsm12133-note-0013){ref-type="fn"}   0.050 (−0.033, 0.134)      0.229
  Hip abduction during stance                                                                                                                                                                     
  0 months                                   0.777 ± 0.096                                                0.804 ± 0.096                                                                           
  6 months                                   0.825 ± 0.098                                                0.812 ± 0.100                                                                           
  12 months                                  0.809 ± 0.073[\*](#jcsm12133-note-0011){ref-type="fn"}       0.831 ± 0.085[\*](#jcsm12133-note-0011){ref-type="fn"}       0.006 (−0.048, 0.059)      0.836
  Knee extension during early stance                                                                                                                                                              
  0 months                                   0.686 ± 0.198                                                0.619 ± 0.192                                                                           
  6 months                                   0.593 ± 0.231                                                0.507 ± 0.178                                                                           
  12 months                                  0.504 ± 0.191[\*\*\*](#jcsm12133-note-0013){ref-type="fn"}   0.546 ± 0.150[\*\*\*](#jcsm12133-note-0013){ref-type="fn"}   −0.109 (−0.199, −0.018)    0.019
  Ankle subtalar inversion during stance                                                                                                                                                          
  0 months                                   0.245 ± 0.072                                                0.274 ± 0.088                                                                           
  6 months                                   0.275 ± 0.086                                                0.259 ± 0.082                                                                           
  12 months                                  0.270 ± 0.082                                                0.273 ± 0.092                                                0.026 (−0.006, 0.059)      0.113
  Ankle plantar flexion during late stance                                                                                                                                                        
  0 months                                   1.334 ± 0.112                                                1.410 ± 0.100                                                                           
  6 months                                   1.338 ± 0.120                                                1.453 ± 0.100                                                                           
  12 months                                  1.399 ± 0.100[\*\*](#jcsm12133-note-0012){ref-type="fn"}     1.437 ± 0.116[\*\*](#jcsm12133-note-0012){ref-type="fn"}     0.039 (−0.022, 0.099)      0.203

ADT, androgen deprivation treatment; CI, confidence interval.

Peak torque (Newton‐metres) was adjusted for body weight (kilogram) and leg length. Data are presented as mean ± standard deviation. *P* \< 0.05 was considered statistically significant. Mean difference refers to the between group difference, which is the difference in the change in the mean of the ADT group over change in the mean of the control group over 12 months and is presented with \[95% confidence interval (CI)\] and *P* value (determined from the interaction effect of the mixed model). There were no statistically significant interactions between 0 and 6 months.

*P* \< 0.05.

*P* \< 0.01.

*P* \< 0.001 refers to a significant within group difference in the mean 12 month value and the mean 0 month value within the group (determined from the time effect of the mixed model and paired *t*‐test).

###### 

Individual muscle contributions to acceleration of the body\'s centre of mass in the vertical, anteroposterior, and mediolateral directions

  Accelerations m/s                                                                              ADT group (*n* = 29)                                       Controls (*n* = 24)                                        Mean difference (95% CI)   *P* value
  ---------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- -------------------------- -----------
  Vertical (upwards) acceleration                                                                                                                                                                                                                 
  Peak gluteus medius during early stance                                                                                                                                                                                                         
  0 months                                                                                       2.49 ± 0.41                                                2.61 ± 0.41                                                                           
  6 months                                                                                       2.61 ± 0.42                                                2.66 ± 0.47                                                                           
  12 months                                                                                      2.61 ± 0.41[\*\*](#jcsm12133-note-0017){ref-type="fn"}     2.73 ± 0.44[\*\*](#jcsm12133-note-0017){ref-type="fn"}     −0.001 (−0.14, 0.14)       0.987
  Peak gluteus maximus during early stance                                                                                                                                                                                                        
  0 months                                                                                       2.74 ± 0.92                                                2.92 ± 0.69                                                                           
  6 months                                                                                       3.07 ± 0.85                                                3.27 ± 0.85                                                                           
  12 months                                                                                      3.23 ± 0.76[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   3.32 ± 0.91[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   0.10 (−0.29, 0.49)         0.624
  Peak hamstrings during early stance                                                                                                                                                                                                             
  0 months                                                                                       0.84 ± 0.45                                                0.89 ± 0.44                                                                           
  6 months                                                                                       0.81 ± 0.36                                                0.88 ± 0.46                                                                           
  12 months                                                                                      0.96 ± 0.48                                                0.89 ± 0.48                                                0.12 (−0.05, 0.29)         0.160
  Peak quadriceps during early stance                                                                                                                                                                                                             
  0 months                                                                                       4.45 ± 1.41                                                4.07 ± 1.10                                                                           
  6 months                                                                                       3.96 ± 1.59                                                3.58 ± 1.10                                                                           
  12 months                                                                                      3.58 ± 1.26[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   3.73 ± 1.04[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   −0.53 (−1.09, 0.03)        0.063
  Peak gastrocnemius during late stance                                                                                                                                                                                                           
  0 months                                                                                       1.91 ± 0.66                                                1.84 ± 0.55                                                                           
  6 months                                                                                       1.92 ± 0.78                                                2.10 ± 0.54                                                                           
  12 months                                                                                      2.13 ± 0.83[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   2.10 ± 0.59[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   −0.04 (−0.29, 0.21)        0.737
  Peak soleus during late stance                                                                                                                                                                                                                  
  0 months                                                                                       6.75 ± 0.52                                                6.83 ± 0.62                                                                           
  6 months                                                                                       6.54 ± 0.62                                                6.82 ± 0.59                                                                           
  12 months                                                                                      6.73 ± 0.50                                                6.89 ± 0.56                                                −0.08 (−0.35, 0.19)        0.558
  Anteroposterior acceleration (anterior/forwards = propulsion, posterior/backwards = braking)                                                                                                                                                    
  Peak gluteus medius contribution to braking                                                                                                                                                                                                     
  0 months                                                                                       0.32 ± 0.11                                                0.38 ± 0.14                                                                           
  6 months                                                                                       0.38 ± 0.12                                                0.39 ± 0.16                                                                           
  12 months                                                                                      0.39 ± 0.16[\*\*](#jcsm12133-note-0017){ref-type="fn"}     0.44 ± 0.19[\*\*](#jcsm12133-note-0017){ref-type="fn"}     0.02 (−0.06, 0.10)         0.663
  Peak gluteus maximus contribution to braking                                                                                                                                                                                                    
  0 months                                                                                       0.58 ± 0.20                                                0.67 ± 0.20                                                                           
  6 months                                                                                       0.66 ± 0.17                                                0.76 ± 0.21                                                                           
  12 months                                                                                      0.72 ± 0.19[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   0.76 ± 0.18[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   0.06 (−0.06, 0.17)         0.328
  Peak quadriceps contribution to braking                                                                                                                                                                                                         
  0 months                                                                                       1.86 ± 0.50                                                1.78 ± 0.38                                                                           
  6 months                                                                                       1.70 ± 0.57                                                1.57 ± 0.39                                                                           
  12 months                                                                                      1.58 ± 0.44[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   1.63 ± 0.37[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   −0.14 (−0.34, 0.05)        0.140
  Peak iliopsoas contribution to propulsion                                                                                                                                                                                                       
  0 months                                                                                       0.44 ± 0.21                                                0.50 ± 0.17                                                                           
  6 months                                                                                       0.49 ± 0.16                                                0.55 ± 0.21                                                                           
  12 months                                                                                      0.55 ± 0.25[\*\*](#jcsm12133-note-0017){ref-type="fn"}     0.54 ± 0.16[\*\*](#jcsm12133-note-0017){ref-type="fn"}     0.07 (−0.04, 0.18)         0.221
  Peak gastrocnemius contribution to propulsion                                                                                                                                                                                                   
  0 months                                                                                       0.54 ± 0.15                                                0.58 ± 0.15                                                                           
  6 months                                                                                       0.52 ± 0.15                                                0.55 ± 0.14                                                                           
  12 months                                                                                      0.55 ± 0.13                                                0.57 ± 0.16                                                0.02 (−0.05, 0.08)         0.628
  Peak Soleus contribution to propulsion                                                                                                                                                                                                          
  0 months                                                                                       1.00 ± 0.24                                                0.82 ± 0.17                                                                           
  6 months                                                                                       0.86 ± 0.30                                                0.73 ± 0.14                                                                           
  12 months                                                                                      0.78 ± 0.26[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   0.78 ± 0.19[\*\*\*](#jcsm12133-note-0018){ref-type="fn"}   −0.17 (−0.29, −0.05)       0.005
  Mediolateral (sideways) acceleration[a](#jcsm12133-note-0019){ref-type="fn"}                                                                                                                                                                    
  Peak gluteus medius                                                                                                                                                                                                                             
  0 months                                                                                       −1.09 ± 0.14                                               −1.11 ± 0.14                                                                          
  6 months                                                                                       −1.11 ± 0.14                                               −1.12 ± 0.14                                                                          
  12 months                                                                                      −1.11 ± 0.14                                               −1.10 ± 0.15                                               −0.03 (−0.09, 0.03)        0.28

ADT, androgen deprivation treatment; CI, confidence interval.

Data are presented as mean ± standard deviation. *P* \< 0.05 was considered statistically significant. Mean difference refers to the between group difference, which is the difference in the change in the mean of the ADT group over change in the mean of the control group over 12 months and is presented with \[95% confidence interval (CI)\] and *P* value (determined from the interaction effect of the mixed model). There were no statistically significant interactions between 0 and 6 months.

*P* \< 0.05.

*P* \< 0.01.

*P* \< 0.001 refers to a significant within group difference in the mean 12 month value and the mean 0 month value within the group (determined from the time effect of the mixed model and paired *t*‐test).

Negative values refer to medial accelerations and positive values refer to lateral accelerations.

Results {#jcsm12133-sec-0015}
=======

Baseline characteristics of both groups prior to ADT commencement are shown in *Table* [1](#jcsm12133-tbl-0001){ref-type="table-wrap"}. At baseline, all men had normal testosterone levels for age and were matched for age, radiotherapy status, and medical co‐morbidities. Inevitably, the two groups differed in their prostate cancer characteristics, consistent with indications for ADT treatment; the ADT group had high‐risk prostate cancer, whereas controls predominantly had intermediate‐risk disease (*Table* [1](#jcsm12133-tbl-0001){ref-type="table-wrap"}). These different risks are solely based on the Gleason score and PSA levels and were not expected to impact on physical performance.

In the ADT treated group, total testosterone levels and consequently PSA, lean body mass and hand‐grip strength significantly declined compared with controls over 12 months (*Table* [2](#jcsm12133-tbl-0002){ref-type="table-wrap"}). Self‐reported physical activity levels were unchanged over time in both groups.

 {#jcsm12133-sec-0016}

### Net joint torques and lower‐limb muscle forces {#jcsm12133-sec-0017}

Mean differences between the change in the ADT group and the change in the control group are presented in *Table* [3](#jcsm12133-tbl-0003){ref-type="table-wrap"} with corresponding *P* values. Asterisks in *Table* [3](#jcsm12133-tbl-0003){ref-type="table-wrap"} highlight significance within group differences from 0 to 12 months for each calculated joint torque. Compared with controls over 12 months, men receiving ADT had a significant reduction in two joint torques; hip flexion and knee extension.

Peak hip flexor torque during late stance reduced by 14% \[−0.108 (−0.189, −0.028) N m/kg, *P* = 0.009\] over 12 months relative to the initial mean value (*Table* [3](#jcsm12133-tbl-0003){ref-type="table-wrap"}) mediated by a reduction in iliopsoas force in the ADT group (1.72 ± 0.37 times BW to 1.38 ± 0.36 times BW) compared with controls (1.66 ± 0.40 times BW to 1.56 ± 0.46 times BW), with a mean difference of −0.24 (−0.41, −0.07) times BW, *P* = 0.006. For the mean subject participant BW of 85 kg, this equated to a reduction of 20 kg in iliopsoas force (25%).

Peak knee extension torque during midstance also had a mean reduction of 16% \[−0.109 (−0.199, −0.018) N m/kg, *P* = 0.019\] over 12 months mediated predominantly by quadriceps. While the decrease in quadriceps force in the ADT group (1.54 ± 0.48 times BW to 1.25 ± 0.44 times BW) compared with controls (1.39 ± 0.34 times BW to 1.28 ± 0.35 times BW) was more marked \[mean difference −0.17 (−0.36, 0.02) times BW, *P* = 0.073\], this finding narrowly missed statistical significance. There were no other significant differences in individual muscle forces (data not shown).

No statistically significant between group changes in joint torques were observed at 6 months.

### Individual muscle contributions to centre of mass accelerations {#jcsm12133-sec-0018}

Individual muscle contributions to acceleration of the body\'s centre of mass in three directions are shown in *Table* [4](#jcsm12133-tbl-0004){ref-type="table-wrap"}. Compared with controls, the ADT group had decreased contribution from the soleus to anterior acceleration (forward propulsion) of the body\'s centre of mass by 17% of the ADT group\'s initial mean value over 12 months (*Table* [4](#jcsm12133-tbl-0004){ref-type="table-wrap"}). No significant changes were observed at 6 months.

### Step width, walking speed, and stride length {#jcsm12133-sec-0019}

Compared with controls over 12 months, the ADT group had a mean increase in step width of 18% (*Figure* [4](#jcsm12133-fig-0004){ref-type="fig"}C). There were no significant changes in walking speed, stride length (*Figure* [4](#jcsm12133-fig-0004){ref-type="fig"}A and 4B) or ground reaction forces over time (data not shown).

![Temporal‐spatial parameters. Mean difference refers to the difference in the change in the mean of the ADT group over change in the mean of the control group over 12 months and is presented with (95% confidence interval) and *P* value. ^\#^ *P* \< 0.05 represents a significant difference in the change in the mean of the ADT group compared with the change in the control group over 12 months (main outcome). ^\*^ *P* \< 0.05 represents a significant difference between the mean 12‐month value and mean baseline value within the same group. No significant interactions were observed from 0 to 6 months. Box plots demonstrate median, interquartile range, and range. The diamond represents the mean and the 95% confidence interval of the mean.](JCSM-8-102-g004){#jcsm12133-fig-0004}

Discussion {#jcsm12133-sec-0020}
==========

Using quantitative gait analysis in conjunction with computerized musculoskeletal modelling, we report that ADT was associated with selective decrements in lower‐limb muscle function; specifically, peak hip flexor torque reduced by 14% in the ADT group, mediated by a reduction in iliopsoas force; knee extensor torque reduced by 16%, mediated by a reduction in quadriceps force; soleus\' contribution to forward acceleration (propulsion) of the body reduced by 17%; and step width increased by 18%. These biomechanical changes were evident for walking at self‐selected speeds, a key functional activity of daily living but became detectable only after 12 months of androgen deprivation. The objective deficits in muscle function associated with ADT over time demonstrated here are in keeping with subjective reports of decreased physical aspects of quality of life demonstrated in prior studies.[8](#jcsm12133-bib-0008){ref-type="ref"}

Despite causing systemic testosterone deprivation, and a decrease in total body lean mass, ADT did not affect all lower‐limb muscles equally. Instead, testosterone deprivation led to selective impairments in lower limb muscle function, predominantly affecting muscles involved in generating vertical support, accelerating the body forward (propulsion), and preparing the leg for the swing phase; namely, quadriceps, soleus, and iliopsoas, respectively. Selective effects are similarly seen in mouse models of testosterone deficiency, where these animals show more marked reductions in levator ani and hind‐limb muscles.[24](#jcsm12133-bib-0024){ref-type="ref"}, [25](#jcsm12133-bib-0025){ref-type="ref"}

We found that men receiving ADT walked with a wider base of support by increasing their step width by 14 mm. This magnitude is considered a clinically meaningful change.[26](#jcsm12133-bib-0026){ref-type="ref"} This finding may provide an explanation for observational studies that have associated low testosterone with balance impairment and self‐reported falls.[27](#jcsm12133-bib-0027){ref-type="ref"} Interestingly, noting that testosterone levels gradually decline with aging, increased step width has been shown to be a good discriminator between older and younger adults in cross‐sectional studies.[28](#jcsm12133-bib-0028){ref-type="ref"}, [29](#jcsm12133-bib-0029){ref-type="ref"}

Despite previous studies demonstrating that loss of muscle mass occurs early, within the first 3 to 6 months of ADT,[5](#jcsm12133-bib-0005){ref-type="ref"}, [30](#jcsm12133-bib-0030){ref-type="ref"} we observed no change in muscle function at 6 months and significant decrements were only evident after 12 months of androgen deprivation. Changes in muscle mass do not necessarily equate to changes in muscle function supporting the importance of distinguishing between these two parameters.[31](#jcsm12133-bib-0031){ref-type="ref"}

Our findings may have implications for mitigating adverse effects for men receiving ADT for non‐metastatic prostate cancer, as well as for aging‐associated functional limitations. The functional deficits reported here identify specific targets for clinical trials to improve ADT and potentially aging‐associated sarcopenia. Strengthening of the knee extensor muscles may be particularly important, consistent with previous studies demonstrating that functional deficits in quadriceps are associated with mobility limitation and the age‐associated testosterone decline.[32](#jcsm12133-bib-0032){ref-type="ref"}

There are limitations to this study. Our gait experiments did not assess strenuous activity or maximal voluntary muscle capacity. It is possible that ADT may lead to even more significant functional deficits with strenuous activity or endurance, which cannot be assessed with the methodology used here. However, we performed an in‐depth analysis of muscle function during walking, the most common and relevant activity of daily living for older adults. Secondly, a group of healthy controls was not included as the aim of the study was to specifically examine the effects of ADT. Hence, we used prostate cancer controls matched for co‐morbidities including cancer diagnosis, age, and radiotherapy status. Indications for ADT inevitably limited the ability to match for grade of prostate cancer. Therefore, men receiving ADT had, at baseline, higher histological grade (Gleason score 9 vs. 7 in controls) and higher PSA levels (3.62 vs. 0.05 µg/L). We cannot exclude the possibility that the between group differences in prostate cancer grade could have different effects on sarcopenia and muscle function over time. However, consequent to radiotherapy, PSA levels decreased in ADT‐treated men at 6 months and remained low at 12 months, with no difference to controls (*Table* [2](#jcsm12133-tbl-0002){ref-type="table-wrap"}). Most importantly, all study participants had localized disease without evidence of metastases on baseline staging investigations, were fully active, unrestricted in their physical activities, and had a normal performance status. Thirdly, physical activity was not standardized. While self‐reported questionnaires demonstrated no change in leisure‐time physical activity levels, we cannot exclude the possibility that the mechanisms by which ADT led to the gait impairments included reduced physical activity.

However, the strengths of this study are significant and include the first application of this methodology to longitudinal studies in humans. This allowed the identification of specific deficits in gait biomechanics, which provide new insights into the biology of androgen action in human skeletal muscle. Identification of a precise method to study the effects of ADT and possibly androgens in age‐related frailty is valuable, given the contradictory results of previous functional studies and that there are currently no effective treatment strategies, which have demonstrated a consistent benefit on function. Application of this methodology to interventional trials has the potential to develop strategies targeted to the specific deficits to prevent loss of muscle mass and functional deficits associated with ADT, to ultimately improve physical functioning, an important aspect of quality of life for many patients with prostate cancer.

In summary, this longitudinal study has demonstrated that ADT leads to selective decrements in lower‐limb muscle function, particularly affecting muscles that generate support and forward propulsion of the body, with muscles responsible for balance also adversely affected. The gait phenotype identified here may provide a rational basis to guide exercise and promyogenic pharmacotherapy in clinical trials to mitigate ADT‐associated sarcopenia and improve outcomes for men with prostate cancer.
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